Featured Research

from universities, journals, and other organizations

Gelatin-based nanoparticle treatment may be a more effective clot buster

Date:
December 1, 2011
Source:
American Heart Association
Summary:
A targeted, nanoparticle gelatin-based clot-busting treatment dissolved significantly more blood clots than a currently used drug in an animal study of acute coronary syndrome.

A targeted, nanoparticle gelatin-based clot-busting treatment dissolved significantly more blood clots than a currently used drug in an animal study of acute coronary syndrome presented at the American Heart Association's Scientific Sessions 2011.

The new drug-delivery system used gelatin to deactivate the clot-busting drug tissue plasminogen activator, or tPA, to treat acute coronary syndrome. Soundwaves were then used to reactivate tPA once it reached the blood clot. It is considered a stealth approach because tPA doesn't act until it has reached its target.

"When tPA is mixed with gelatin and administered in the form of nanoparticles, it reduces tPA activity. Inactivation of tPA during circulation is very important to reduce bleeding complications," said Yoshihiko Saito, M.D., senior author and professor and cardiologist at Nara Medical University in Kashihara, Japan.

This gelatin-based drug-delivery system could potentially treat patients with chest pain en route to the hospital via ambulance.

Traditionally, tPA is administered in the hospital, injected through a vein in the arm or a catheter inserted into the groin and guided directly into the blocked vessel.

Prompt clot-busting therapy, or thrombolysis, restores blood flow to the heart and can often prevent death. When a clot completely blocks a blood vessel, the recommended treatment is emergency angioplasty, when a tiny metal mesh tube is inserted into the artery to prop it open. However, about half of the patients who die from acute coronary syndrome do not reach the hospital in time to receive appropriate therapy.

"This drug delivery system aims to quickly restore blood flow. Restoring blood flow reduces tissue damage and improves the prognosis," Saito said.

The body naturally produces tPA, which helps prevent blood clots by inhibiting certain proteins involved in the clotting process. Gelatin also binds these proteins -- in particular the von Willebrand factor, which in this study responded to gelatin combined with tPA, but not to tPA alone.

Tracking the drug using radioactive tPA, scientists analyzed blood clots in animals and found three times more nanoparticle tPA than regular isolated tPA. Thirty minutes after administerting drugs in a different animal model, blood flow was partially or completed restored in:

  • 10 percent with tPA alone;
  • 40 percent with tPA and ultrasound; and
  • 90 percent with drug-delivery system of tPA /nanoparticle and ultrasound.

Acute coronary syndrome -- when blood flow to the heart decreases abruptly -- affects up to 1.2 million Americans each year. This includes chest pain and heart attacks.

Co-authors are Hiroyuki Kawata, M.D.; Tsunenari Soeda, M.D.; Yasuhiro Takemoto, M.D.; Ji-Hi Sung, M.D.; Yoshiko Uesugi, B.Sc.; Yasuhiko Tabata, Ph.D.; Kiyotaka Umaki, Ph.D.; Keiji Kato, Ph.D.; and Shiro Uemura, M.D.


Story Source:

The above story is based on materials provided by American Heart Association. Note: Materials may be edited for content and length.


Cite This Page:

American Heart Association. "Gelatin-based nanoparticle treatment may be a more effective clot buster." ScienceDaily. ScienceDaily, 1 December 2011. <www.sciencedaily.com/releases/2011/11/111114152358.htm>.
American Heart Association. (2011, December 1). Gelatin-based nanoparticle treatment may be a more effective clot buster. ScienceDaily. Retrieved July 24, 2014 from www.sciencedaily.com/releases/2011/11/111114152358.htm
American Heart Association. "Gelatin-based nanoparticle treatment may be a more effective clot buster." ScienceDaily. www.sciencedaily.com/releases/2011/11/111114152358.htm (accessed July 24, 2014).

Share This




More Health & Medicine News

Thursday, July 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
China's Ageing Millions Look Forward to Bleak Future

China's Ageing Millions Look Forward to Bleak Future

AFP (July 24, 2014) China's elderly population is expanding so quickly that children struggle to look after them, pushing them to do something unexpected in Chinese society- move their parents into a nursing home. Duration: 02:07 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins